Genetic stability of live, cold-adapted influenza virus components of the FluMist super([registered])/CAIV-T vaccine throughout the manufacturing process

• Published in: Vaccine Vol. 24; no. 12; pp. 2151 - 2160
• Main Authors: Buonagurio, Deborah A, Bechert, Thomas M, Yang, Chin-Fen, Shutyak, Leonid, D'Arco, Gail A, Kazachkov, Yuriy, Wang, Hai-Ping, Rojas, Eduardo A, O'Neill, Robert E, Spaete, Richard R, Coelingh, Kathleen L, Zamb, Timothy J, Sidhu, Mohinder S, Udem, Stephen A
• Format: Journal Article
• Language: English
• Published: 01-01-2006
• Subjects: Influenza virus
• ISSN: 0264-410X
• DOI: 10.1016/j.vaccine.2005.11.007

FluMist super([registered]) is a live-attenuated, trivalent influenza vaccine (LAIV) recently approved for intranasal administration. To demonstrate genetic stability during manufacture of the vaccine viruses in LAIV and a similar vaccine in development (CAIV-T), full genome consensus sequences were determined at multiple manufacturing stages for four influenza type A and five type B strains. The critical cold-adapted (ca), temperature-sensitive (ts) and attenuated (att) mutations were preserved in the virus manufacturing intermediates. Moreover, sequence identity was observed for all vaccine intermediates of the same strain. Minor sequence differences were noted in the shared gene segments of the vaccine viruses and their common progenitor master donor virus (MDV) and several of the hemagglutinin (HA) and neuraminidase (NA) genes contained nucleotide differences when compared to the wild-type parent. Nonetheless, all vaccine viruses retained the ca, ts, and att phenotypes. Thus, genetic and phenotypic stability of the vaccine viruses is maintained during the manufacture of LAIV/CAIV-T vaccines.